Arrhythmia
Conditions
Keywords
Arrhythmia, Device Procedure, Antibiotics, Infection, Cluster
Brief summary
The goal of the study is to compare whether a center-wide policy of incremental antibiotic therapy will reduce CIED infection rate compared to a policy of conventional antibiotic prophylaxis in high-risk patients undergoing arrhythmia device procedures. All antibiotics used are approved for use and readily available.
Detailed description
This is a randomized prospective cluster crossover trial to track outcomes of high infection risk patients undergoing arrhythmia device procedures. Centres will be randomized to either conventional antibiotic therapy or incremental antibiotic therapy. Patients will not be randomized. Centres will be randomized to one therapy and then cross over to the next after 6 months. At one year they will randomize again and then cross over for the final time at 18 months. During each treatment period the randomized antibiotic therapy will be used on all centre patients undergoing a device implant procedure. Ethics approval has been obtained in all sites for waiver of consent with notification of the study (i.e. data collection is taking place to track infection rates). A third of sites obtain consent after the procedure for collection of data (but not for care, since either arm is the standard of care).
Interventions
DRUGIncremental
Single dose of Cefazolin and Vancomycin preoperatively, bacitracin wash and cefalexin post operative.
DRUGConventional
Cefazolin preoperative
Sponsors
Canadian Institutes of Health Research (CIHR)
Population Health Research Institute
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Age \>= 18 years 2. Received one of the following procedures: 1. A second or subsequent procedure on the arrhythmia device pocket: ICD, pacemaker, CRT-P, CRT-D generator and/or lead replacement 2. Pocket or lead revision 3. System upgrade (insertion or attempted insertion of leads) 4. New cardiac resynchronization therapy device implant (pacemaker or ICD) 3. Patient is not known to have device infection at the time of the surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hospitalization attributed to device infection | Evaluation is one year post patient's procedure |
Secondary
| Measure | Time frame |
|---|---|
| 1. Proven device infection not requiring surgical intervention (medically treated device infection). | Up to one year post procedure |
| 2. Any treatment with antibiotics for suspected device infection. | Up to one year post procedure |
| 3. Antibiotic-related adverse events including culture or antigen proven C. difficile infection. | Up to one year post procedure |
| 4. Prolongation of hospitalization due to proven or suspected adverse events from the antibiotic therapy. | Up to one year post procedure |
| Cost benefit analysis | At completion of data collection period |
| 6. Rate of device/lead extraction 12 months post patient's procedure (regardless of the cause). | Up to one year post procedure |
Countries
Canada
Outcome results
None listed